Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

"This MAA submission, under an accelerated regulatory pathway, is an important step towards approval of our second product in the EEA and highlights Pharming’s ongoing commitment to advancing leniolisib as a treatment for patients with APDS." — Anurag Relan | Chief Medical Officer Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗